KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Raw Materials (2016 - 2025)

Sarepta Therapeutics has reported Raw Materials over the past 10 years, most recently at $141.3 million for Q4 2025.

  • For Q4 2025, Raw Materials fell 49.55% year-over-year to $141.3 million; the TTM value through Dec 2025 reached $141.3 million, down 49.55%, while the annual FY2025 figure was $141.3 million, 49.55% down from the prior year.
  • Raw Materials for Q4 2025 was $141.3 million at Sarepta Therapeutics, down from $325.5 million in the prior quarter.
  • Over five years, Raw Materials peaked at $325.5 million in Q3 2025 and troughed at $40.2 million in Q3 2021.
  • A 5-year average of $187.9 million and a median of $199.9 million in 2021 define the central range for Raw Materials.
  • On a YoY basis, Raw Materials climbed as much as 294.05% in 2022 and fell as far as 74.29% in 2022.
  • Year by year, Raw Materials stood at $230.2 million in 2021, then plummeted by 74.29% to $59.2 million in 2022, then skyrocketed by 126.36% to $134.0 million in 2023, then soared by 109.05% to $280.0 million in 2024, then plummeted by 49.55% to $141.3 million in 2025.
  • Business Quant data shows Raw Materials for SRPT at $141.3 million in Q4 2025, $325.5 million in Q3 2025, and $314.9 million in Q2 2025.